A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)

PHASE2CompletedINTERVENTIONAL
Enrollment

191

Participants

Timeline

Start Date

September 28, 2021

Primary Completion Date

December 10, 2024

Study Completion Date

December 10, 2024

Conditions
Hematological Malignancies
Interventions
BIOLOGICAL

Pembrolizumab/vibostolimab coformuation

Pembrolizumab 200 mg + vibostolimab 200 mg/20 mL vial IV infusion Q3W up to approximately 2 years.

Trial Locations (65)

333

Chang Gung Medical Foundation-Linkou Branch ( Site 0262), Taoyuan District

1088

Semmelweis University-Belgyógyászati és Hematológiai Klinika ( Site 0403), Budapest

1122

Országos Onkológiai Intézet-HEMATOLÓGIA ÉS LYMPHOMA OSZTÁLY KEMOTERÁPIA A ( Site 0405), Budapest

2100

Rigshospitalet-Hematology - CTU ( Site 0361), Copenhagen

4032

Debreceni Egyetem Klinikai Kozpont-Belgyógyászati Klinika (Haematologia) ( Site 0402), Debrecen

7624

Pécsi Tudományegyetem Klinikai Központ-I.sz. Belgyógyászati Klinika Hematológia ( Site 0401), Pécs

8200

Aarhus Universitetshospital, Skejby-Blodsygdomme ( Site 0362), Aarhus

18009

Cherkasy Regional Oncology Dispensary ( Site 0593), Cherkassy

20132

Ospedale San Raffaele-Unità Linfomi ( Site 0382), Milan

20246

Universitaetsklinikum Hamburg-Eppendorf-II. medical clinic ( Site 0332), Hamburg

25123

Azienda Ospedaliera Spedali Civili di Brescia-Hemathology ( Site 0400), Brescia

28040

Hospital Universitario Fundación Jiménez Díaz-Oncology & Hematology ( Site 0446), Madrid

31008

Clinica Universidad de Navarra ( Site 0444), Pamplona

34214

Mega Medipol-Hematology ( Site 0567), Istanbul

34365

Vehbi Koc Vakfi - Amerikan Hastanesi ( Site 0562), Istanbul

35033

Universitätsklinikum Marburg ( Site 0333), Marburg

35100

Ege University Medicine of Faculty ( Site 0565), Bornova

35340

Dokuz Eylül Üniversitesi-Hematology ( Site 0563), Izmir

37007

Hospital Universitario de Salamanca-Hematology ( Site 0441), Salamanca

40138

"Policlinico S. Orsola- Malpighi-Istituto di Ematologia L. e A. Seragnoli ( Site 0381)", Bologna

45122

Universitaetsklinikum Essen ( Site 0327), Essen

48202

Henry Ford Hospital ( Site 0003), Detroit

50937

Universitaetsklinikum Koeln-Klinik I für Innere Medizin ( Site 0321), Cologne

53226

MEDICAL COLLEGE OF WISCONSIN ( Site 0016), Milwaukee

54290

Klinikum Mutterhaus der Borromäerinnen-Innere Medizin I ( Site 0325), Trier

55139

Ondokuz Mayıs Universitesi ( Site 0564), Samsun

60637

University of Chicago Medical Center ( Site 0005), Chicago

64239

Sourasky Medical Center ( Site 0525), Tel Aviv

69310

centre hospitalier lyon sud-Service Hématologie ( Site 0300), Pierre-Bénite

75013

Pitie Salpetriere University Hospital-Clinical haematology ( Site 0304), Paris

77030

University of Texas MD Anderson Cancer Center ( Site 0014), Houston

79044

Institute of Transfusion Medicine and Blood of the National Academy of Medical Sciences of Ukraine (, Lviv

80045

University of Colorado Anschutz Medical Campus-The Center for Cancer and Blood Disorders ( Site 0021, Aurora

83301

Chang Gung Memorial Hospital at Kaohsiung ( Site 0263), Kaohsiung Niao Sung Dist

91010

City of Hope Comprehensive Cancer Center-Hematology ( Site 0024), Duarte

94800

Gustave Roussy-DITEP ( Site 0301), Villejuif

99208

Medical Oncology Associates, PS ( Site 0001), Spokane

125284

Moscow City Clinical Hospital S.P. Botkin ( Site 0547), Moscow

191024

Russian Scientific Research Institute of Hematology and Blood Transfusion-Hematology ( Site 0542), Saint Petersburg

197341

Almazov National Medical Research Centre-Intensive care unit No. 10 for oncohematological patients (, Saint Petersburg

450054

GBUZ Republican Clinical Oncological Dispensary-Antitumor drug therapy department ( Site 0548), Ufa

3109601

Rambam Health Care Campus ( Site 0526), Haifa

5262100

Sheba Medical Center-Hemato Oncology ( Site 0524), Ramat Gan

6900941

FALP-UIDO ( Site 0623), Santiago

8380455

Instituto Nacional del Cancer ( Site 0626), Chile

8410101

Soroka Medical Center-Hematology Department ( Site 0523), Beersheba

9112001

Hadassah Medical Center ( Site 0522), Jerusalem

80510130

Instituto do Câncer e Transplante de Curitiba ( Site 0611), Curitiba

07601

John Theurer Cancer Center at Hackensack University Medical Center ( Site 0004), Hackensack

08901

Rutgers Cancer Institute of New Jersey ( Site 0023), New Brunswick

59075-740

Liga Norte Riograndense Contra o Câncer-Centro de Pesquisa Clínica ( Site 0601), Natal

V5Z 4E6

BC Cancer Vancouver ( Site 0034), Vancouver

m5g2m9

Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0031), Toronto

H3T 1E2

Jewish General Hospital ( Site 0032), Montreal

H4A 3J1

McGill University Health Centre ( Site 0037), Montreal

04103

Universitätsklinikum Leipzig ( Site 0328), Leipzig

00168

Fondazione Policlinico Universitario Agostino Gemelli-ISTITUTO DI EMATOLOGIA ( Site 0383), Rome

50-556

Uniwersytecki Szpital Kliniczny-Klinika Hematologii, Nowotworow Krwi i Transplantacji Szpiku ( Site, Wrocaw

02-781

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworów Układu Chłonnego ( S, Warsaw

80-214

Uniwersyteckie Centrum Kliniczne-Klinika Hematologii i Transplantologii ( Site 0424), Gdansk

44-101

Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 0427), Gliwice

08908

Instituto Catalan de Oncologia - Hospital Duran i Reynals-Haematology Department ( Site 0442), L'Hospitalet Del Llobregat

06100

Ankara University Hospital Cebeci ( Site 0561), Ankara

03022

National Cancer Institute ( Site 0585), Kyiv

Unknown

National Research Center for Radiation Medicine of National Academy of Medical Sciences of Ukraine (, Kyiv

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT05005442 - A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004) | Biotech Hunter | Biotech Hunter